Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Purchased by Rock Springs Capital Management LP

Rock Springs Capital Management LP increased its position in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 15.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 955,106 shares of the company’s stock after purchasing an additional 127,005 shares during the period. Rock Springs Capital Management LP owned 0.59% of Neumora Therapeutics worth $10,124,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Capital International Investors raised its position in shares of Neumora Therapeutics by 692.1% during the 4th quarter. Capital International Investors now owns 3,700,359 shares of the company’s stock valued at $39,224,000 after buying an additional 3,233,179 shares during the period. State Street Corp grew its position in Neumora Therapeutics by 65.3% in the third quarter. State Street Corp now owns 1,790,707 shares of the company’s stock worth $23,655,000 after acquiring an additional 707,409 shares during the period. Geode Capital Management LLC increased its stake in Neumora Therapeutics by 54.0% during the third quarter. Geode Capital Management LLC now owns 1,979,847 shares of the company’s stock worth $26,159,000 after acquiring an additional 694,385 shares during the last quarter. Vanguard Group Inc. raised its position in Neumora Therapeutics by 4.5% in the fourth quarter. Vanguard Group Inc. now owns 4,572,308 shares of the company’s stock valued at $48,466,000 after purchasing an additional 195,142 shares during the period. Finally, Swiss National Bank purchased a new stake in Neumora Therapeutics in the fourth quarter valued at $1,168,000. 47.65% of the stock is owned by hedge funds and other institutional investors.

Neumora Therapeutics Stock Up 2.7 %

Shares of NMRA opened at $0.65 on Monday. Neumora Therapeutics, Inc. has a fifty-two week low of $0.62 and a fifty-two week high of $17.19. The company has a market cap of $104.62 million, a P/E ratio of -0.35 and a beta of 2.89. The firm’s 50 day moving average price is $1.20 and its 200 day moving average price is $6.14.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.09. Research analysts forecast that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NMRA has been the subject of a number of recent analyst reports. HC Wainwright cut their price objective on Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. William Blair cut shares of Neumora Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, March 10th. Stifel Nicolaus lowered shares of Neumora Therapeutics from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $6.00 to $2.00 in a report on Friday, March 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 price objective on shares of Neumora Therapeutics in a research report on Thursday, April 10th. Finally, Bank of America reissued an “underperform” rating and issued a $1.00 target price (down previously from $7.00) on shares of Neumora Therapeutics in a research report on Wednesday, April 2nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $9.29.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.